{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:26:59Z","timestamp":1786685219188,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fondazione Romeo ed Enrica Invernizzi, Milan, Italy"},{"id":[{"id":"https:\/\/ror.org\/01hmx0351","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background\/Objectives: Antinuclear antibody testing by indirect immunofluorescence on HEp-2 cells (ANA-IIF) remains the reference test for systemic autoimmune rheumatic diseases (SARD). However, complete serological characterization requires integration with extractable nuclear antigen (ENA) screening, antigen-specific solid-phase assays (SPA), and confirmatory indirect immunofluorescence (IIF) tests. This study aimed to: (1) quantify real-world serological pathway incompleteness in ANA testing performed outside a structured reflex strategy; (2) compare simulated stepwise and upfront parallel reflex approaches in terms of serological yield, laboratory workload, and costs. Methods: We retrospectively analyzed 2207 consecutive patients referred for ANA-IIF testing between July 2025 and April 2026. Serological incompleteness was defined as non-completion of the predefined Regione Lombardia reflex framework. A fully characterized subgroup of 514 patients, defined by complete reflex-serological assessment, was used to compare a stepwise strategy, in which ANA-IIF positivity triggered downstream testing, with an upfront parallel strategy, in which ANA-IIF, ENA screening, and anti-double-stranded DNA (anti-dsDNA) testing were performed upfront. Results: ANA-IIF was positive in 913\/2207 patients (41.4%). Overall, 508 patients (23.0%) had at least one missing follow-up assay expected under the reflex framework. In the fully characterized subgroup, the upfront parallel strategy increased the number of patients with at least one fully characterized autoantibody finding from 15 to 22 (+1.4%), but required 657 additional tests and an estimated incremental cost of approximately \u20ac2592. Conclusions: ANA-IIF testing outside a structured reflex pathway frequently resulted in incomplete serological assessment. Although the upfront parallel strategy increased serological yield, it required substantially greater laboratory workload and costs than the stepwise approach. Further studies are needed to define the optimal balance between serological yield, clinical relevance, and cost-effectiveness.<\/jats:p>","DOI":"10.3390\/biomedicines14081815","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:02:11Z","timestamp":1786532531000},"page":"1815","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evaluation of ANA Testing Pathways: Serological Incompleteness and Comparison of Stepwise Versus Upfront Parallel Reflex Strategies"],"prefix":"10.3390","volume":"14","author":[{"given":"Raffaele","family":"Radice","sequence":"first","affiliation":[{"name":"UOC Laboratory of Clinical Medicine with Specialized Areas, IRCCS MultiMedica Hospital, 20138 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1421-8326","authenticated-orcid":false,"given":"Francesca","family":"Carreras","sequence":"additional","affiliation":[{"name":"UOC Laboratory of Clinical Medicine with Specialized Areas, IRCCS MultiMedica Hospital, 20138 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4068-7607","authenticated-orcid":false,"given":"Chiara","family":"Corrado","sequence":"additional","affiliation":[{"name":"UOC Laboratory of Clinical Medicine with Specialized Areas, IRCCS MultiMedica Hospital, 20138 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9678-0942","authenticated-orcid":false,"given":"Michela","family":"Salvatici","sequence":"additional","affiliation":[{"name":"UOC Laboratory of Clinical Medicine with Specialized Areas, IRCCS MultiMedica Hospital, 20138 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia Francesca","family":"Sansico","sequence":"additional","affiliation":[{"name":"UOC Laboratory of Clinical Medicine with Specialized Areas, IRCCS MultiMedica Hospital, 20138 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bianchi","sequence":"additional","affiliation":[{"name":"UOC Laboratory of Clinical Medicine with Specialized Areas, IRCCS MultiMedica Hospital, 20138 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gaimarri","sequence":"additional","affiliation":[{"name":"UOC Laboratory of Clinical Medicine with Specialized Areas, IRCCS MultiMedica Hospital, 20138 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-1377","authenticated-orcid":false,"given":"Lucia","family":"La Sala","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy"},{"name":"Laboratory of Diabetology, Dysmetabolic Diseases, and Advanced Clinical Research\u2014IRCCS MultiMedica, IRCCS MultiMedica, Via Fantoli 16\/15, 20138 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-0780","authenticated-orcid":false,"given":"Elena","family":"Dozio","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy"},{"name":"Experimental Laboratory for Research on Organ Damage Biomarkers, Istituto Auxologico Italiano, IRCCS, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-540X","authenticated-orcid":false,"given":"Lorenzo","family":"Drago","sequence":"additional","affiliation":[{"name":"UOC Laboratory of Clinical Medicine with Specialized Areas, IRCCS MultiMedica Hospital, 20138 Milan, Italy"},{"name":"Clinical Microbiology and Microbiome Laboratory, Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.autrev.2017.12.008","article-title":"Antinuclear antibodies: Is indirect immunofluorescence still the gold standard or should it be replaced by solid-phase assays?","volume":"17","author":"Gilburd","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5114\/reum.2018.77976","article-title":"Antinuclear antibodies in healthy people and non-rheumatic diseases: Diagnostic and clinical implications","volume":"56","author":"Rogacka","year":"2018","journal-title":"Reumatologia"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pashnina, I.A., Krivolapova, I.M., Fedotkina, T.V., Ryabkova, V.A., Chereshneva, M.V., Churilov, L.P., and Chereshnev, V.A. (2021). Antinuclear autoantibodies in health: Autoimmunity is not a synonym of autoimmune disease. Antibodies, 10.","DOI":"10.3390\/antib10010009"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13317-016-0080-3","article-title":"The ANA-reflex test as a model for improving clinical appropriateness in autoimmune diagnostics","volume":"7","author":"Tonutti","year":"2016","journal-title":"Autoimmun. Highlights"},{"key":"ref_5","unstructured":"Regione Lombardia, Direzione Generale Welfare (2025). Decreto n. 4785 del 4 aprile 2025. Servizi di medicina di laboratorio: Integrazione e aggiornamento dei Sub-Allegati 1 e 4 della DGR n. XI\/7044 del 26 settembre 2022\u2014Anno 2025, Regione Lombardia."},{"key":"ref_6","unstructured":"(2026, June 13). International Consensus on ANA Patterns (ICAP). ANA Patterns. Available online: https:\/\/www.anapatterns.org\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e23914","DOI":"10.1002\/jcla.23914","article-title":"Comparison of the analytical and clinical performances of two different routine testing protocols for antinuclear antibody screening","volume":"35","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.autrev.2017.12.007","article-title":"The association of solid-phase assays with immunofluorescence increases the diagnostic accuracy of ANA screening in patients with autoimmune rheumatic diseases","volume":"17","author":"Bizzaro","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0009-8981(03)00182-7","article-title":"Appropriateness of autoantibody testing in clinical medicine","volume":"333","author":"Wiik","year":"2003","journal-title":"Clin. Chim. Acta"},{"key":"ref_10","first-page":"6","article-title":"Interpretative comments in autoimmune reporting: A proposal for diagnostic harmonization and appropriateness from the Study Group on Autoimmunology of the Italian Society of Clinical Pathology and Laboratory Medicine","volume":"22","author":"Muraro","year":"2026","journal-title":"Riv. Ital. Med. Lab."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Irure-Ventura, J., and L\u00f3pez-Hoyos, M. (2022). The past, present, and future of antinuclear antibodies. Diagnostics, 12.","DOI":"10.3390\/diagnostics12030647"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2011.06.006","article-title":"Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: Conclusive results","volume":"11","author":"Bonaguri","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e000984","DOI":"10.1136\/lupus-2023-000984","article-title":"Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: Does a gold-standard dsDNA assay exist?","volume":"10","author":"Navas","year":"2023","journal-title":"Lupus Sci. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1515\/cclm-2013-0926","article-title":"The accuracy of the anti-mitochondrial antibody and M2 subtype tests for the diagnosis of primary biliary cirrhosis: A meta-analysis","volume":"52","author":"Hu","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100366","DOI":"10.1016\/j.jtauto.2026.100366","article-title":"Autoantibodies in the diagnosis, prognosis, and follow-up of primary biliary cholangitis","volume":"12","author":"Bencze","year":"2026","journal-title":"J. Transl. Autoimmun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3748\/wjg.v29.i12.1795","article-title":"Role of autoantibodies in the clinical management of primary biliary cholangitis","volume":"29","author":"Rigopoulou","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102463","DOI":"10.1016\/j.autrev.2020.102463","article-title":"A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus","volume":"19","author":"Choi","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Radice, R., Pollaroli, G., Salvatici, M., Corrado, C., Rispoli, F., Pacchetti, S., and Drago, L. (2026). The role of laboratory markers in primary biliary cholangitis: A clinical review and a case report. Biomedicines, 14.","DOI":"10.3390\/biomedicines14040925"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41584-020-00522-w","article-title":"Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases","volume":"16","author":"Bossuyt","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100298","DOI":"10.1016\/j.jtauto.2025.100298","article-title":"An international multicentre retrospective analysis of repeated anti-ENA testing in ANA-associated rheumatic diseases: A data-driven proposal to increase testing efficacy","volume":"11","author":"Vroemen","year":"2025","journal-title":"J. Transl. Autoimmun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Dhaouadi, T., Zamali, I., Ben Hmid, A., Guizani, M., Riahi, A., Ben Abdallah, T., Samoud, S., Gorgi, Y., Galai, Y., and Sfar, I. (2026). Frequency of extractable nuclear antigen seropositivity among individuals seronegative for antinuclear antibodies on indirect immunofluorescence: A systematic review and meta-analysis. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1745828"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3121\/cmr.2024.1937","article-title":"The relative timing, outcomes, and economic impact of antinuclear antibody and extractable nuclear antigen laboratory ordering","volume":"22","author":"Ethington","year":"2024","journal-title":"Clin. Med. Res."},{"key":"ref_24","first-page":"e93419","article-title":"Diagnostic utility of antibodies to extractable nuclear antigens in the absence of positive antinuclear antibodies","volume":"17","author":"Huang","year":"2025","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/acr.24990","article-title":"Frequency and clinical utility of antibodies to extractable nuclear antigen in the setting of a negative antinuclear antibody test","volume":"75","author":"Yeo","year":"2023","journal-title":"Arthritis Care Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jcla.1860090312","article-title":"Detection of autoantibodies to SS-A\/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kDa Ro autoantigen in HEp-2 cells","volume":"9","author":"Fritzler","year":"1995","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1515\/cclm-2023-0209","article-title":"Detection of antinuclear antibodies: Recommendations from EFLM, EASI and ICAP","volume":"61","author":"Bonroy","year":"2023","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4103\/0377-4929.68262","article-title":"Correlation of antinuclear antibody immunofluorescence patterns with immune profile using line immunoassay in the Indian scenario","volume":"53","author":"Sebastian","year":"2010","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"102588","DOI":"10.1016\/j.autrev.2020.102588","article-title":"A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: A pilot study","volume":"19","author":"Infantino","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1515\/cclm-2025-0170","article-title":"A cost-effective assessment for the combination of indirect immunofluorescence and solid-phase assay in ANA screening","volume":"63","author":"Gallo","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cafaro, G., Tromby, F., Castellucci, A., Bistoni, O., Del Papa, B., Dal Pozzolo, R., Bruno, L., Colangelo, A., Lalli, F., and Cruciani, G. (2026). Pre-test probability determines optimal ANA screening strategy: A risk-stratified comparison of indirect immunofluorescence and CTD screen assay. Clin. Chem. Lab. Med., advance online publication.","DOI":"10.1515\/cclm-2026-0348"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/8\/1815\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:32:25Z","timestamp":1786681945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/8\/1815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biomedicines14081815"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines14081815","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}